In-vivo Antimalarial Activity and toxicological effects of methanolic extract of Cocos nucifera (Dwarf Red Variety) husk fibre
No Thumbnail Available
Date
2014
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
We performed a single center retrospective analysis of
84 autologous hemopoietic stem cell transplants done
for AML to characterize the pattern of hemopoietic
engraftment, post-transplant cytopenia and their impact
on survival outcome. Following autologous transplant
and engraftment, 30 patients (35.7%) had a transient
secondary decline in their plt counts, which was not
associated with graft rejection, relapse or infection. The
median time to onset of thrombocytopenia was 59 days
post transplant, with spontaneous recovery after a median
period of 41 days. A secondary decline in ANC also
occurred in eight patients. Patients with secondary plt
decline had a significantly earlier primary plt engraftment
(median 15 days) and a trend towards earlier neutrophil
engraftment compared with patients who maintained
steady plt counts (median 21 days). There was a trend
towards a lower incidence of secondary plt decline in
patients who received BM stem cells compared with those
who received PBSC. No cause was evident for the
occurrence of a secondary cytopenia, and it did not
adversely affect survival. We conclude that secondary
cytopenia is a common and harmless occurrence after
autologous transplant especially from PBSC graft.
Bone Marrow Transplantation (2009) 44, 175–183;
doi:10.1038/bmt.2009.1; published online 9 February 2009
Keywords: acute myeloid leukemia; autologous hemopoietic
stem cell transplant; engraftment kinetics; secondary
platelet decline; secondary cytopenia
Introduction
AML refers to a group of clonal hemopoietic stem cell
disorders, which are characterized by failure of differentiation
and excessive proliferation of the stem cells leading to
accumulation of non-functional immature myeloblasts,
both in peripheral blood and BM. Anthracycline-based
chemotherapeutic regimens, which are conventionally given
for induction of remission, are known to produce CR in
about 60–80% of patients.1–3 However, despite the initial
good response by the myeloblasts to these agents, they are
usually associated with a high rate of resistance and relapse,
and it has been reported that majority of AML patients
who achieve CR following induction will relapse within
12–24 months, and only about 7–34% will be alive and
disease free by 5 years after diagnosis.4–6 Autologous
hemopoietic SCT (AHSCT) has therefore been used in
AML either as a component of consolidation following the
initial CR or as part of salvage therapy for patients in
second remission to improve the poor prognosis associated
with chemotherapy alone.7–9 AHSCT has also been used
for AML patients who do not immediately have matched
allogeneic donors and in elderly patients who are above
60 years of age.10
The pattern of engraftment and hemopoietic recovery
following
Description
Keywords
acute myeloid leukemia;, autologous hemopoietic, secondary cytopenia, stem cell transplant;, engraftment kinetics;, secondary platelet decline;
Citation
Balogun, E.A., Malomo, S.O., Adebayo, J.O., Ishola, A.A., Soladoye, A.O., Kolawole, O.M., Oguntoye, O.S., Babatunde, A.S., & Akinola, O.B. (2014). In-vivo Antimalarial Activity and toxicological effects of methanolic extract of Cocos nucifera (Dwarf Red Variety) husk fibre. Journal of Integrative Medicine; 12(6):504-511.